Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBIT (2019 - 2025)

Historic EBIT for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to -$14.4 million.

  • Pulmonx's EBIT fell 186.85% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.2 million, marking a year-over-year increase of 176.79%. This contributed to the annual value of -$57.7 million for FY2024, which is 683.14% up from last year.
  • Per Pulmonx's latest filing, its EBIT stood at -$14.4 million for Q3 2025, which was down 186.85% from -$14.8 million recorded in Q2 2025.
  • In the past 5 years, Pulmonx's EBIT ranged from a high of -$9.8 million in Q3 2021 and a low of -$16.4 million during Q2 2023
  • Over the past 5 years, Pulmonx's median EBIT value was -$14.4 million (recorded in 2022), while the average stood at -$14.2 million.
  • Per our database at Business Quant, Pulmonx's EBIT crashed by 10468.55% in 2021 and then soared by 1136.59% in 2024.
  • Over the past 5 years, Pulmonx's EBIT (Quarter) stood at -$12.4 million in 2021, then fell by 18.28% to -$14.6 million in 2022, then grew by 4.84% to -$13.9 million in 2023, then grew by 3.61% to -$13.4 million in 2024, then dropped by 7.27% to -$14.4 million in 2025.
  • Its EBIT was -$14.4 million in Q3 2025, compared to -$14.8 million in Q2 2025 and -$14.6 million in Q1 2025.